20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- The FDA has cleared Insulet Corporation's (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes (T1D).
- Omnipod 5 is tubeless automated insulin delivery (AID) system in the U.S. that was initially cleared for use in individuals aged six and older in January 2022.
- Also Read: Insulet Posts Q2 Revenue Beat, Lifts FY22 Guidance.
- In a recent publication by Sherr et al. in Diabetes Care, Omnipod 5 significantly improved time in range and reduced HbA1c and time in hypoglycemia (<70 mg/dL) in very young children (aged 2 – 5.9 years) with type 1 diabetes.
- Related: Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes.
- Healthcare professionals can now prescribe Omnipod 5 to their patients with insurance coverage. Patients can access their prescription through the pharmacy channel, meaning there is no contract or commitment.
- Price Action: PODD shares closed at $267.42 on Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!